Botaneco Signs Feasibility Agreement With Croda to Develop Specialty Crop Oil Formulation

Calgary, Canada (ots/PRNewswire) -

- Program Will Focus on Evaluation of Botaneco's Technology to
add Functionality to Echium oil

Botaneco, a wholly-owned subsidiary of SemBioSys Genetics Inc.,
today announced that it has signed a feasibility agreement with Croda
Enterprise Technology, part of Croda International Plc, an
international manufacturer of speciality ingredients with 2007 sales
of pnds stlg 886.1m. Croda will evaluate the ability of Botaneco's
technology platform to improve the stability and versatility of
Echium Plantagineum (Echium) oil, a speciality oil containing omega-3
fatty acids. Under the terms of the agreement, Botaneco will provide
Croda with material for purposes of chemical and functional analysis,
and to determine the viability of a commercial-scale manufacturing
process.

"This feasibility agreement with Croda demonstrates the breadth
of products and opportunities we can offer our customers and partners
with Botaneco's technology platform," said Andrew Baum, President and
CEO of SemBioSys. "We believe that the potential of our platform to
improve the stability of oils and other labile materials expand the
utility and opportunity for Croda's Echium oil in food, dietary
supplements and personal care applications. We expect to complete the
study and provide Croda with a defined process for manufacturing
commercial amounts of material by the end of 2008."

Echium oil contains stearidonic acid, which is effectively
metabolized to eicosapentanoic acid (EPA). EPA has been shown to
reduce the risk of coronary heart disease and provide
anti-inflammatory benefits in both topical and oral formulations.

About Botaneco

Botaneco is the global developer and marketer of innovative
oleosome-based ingredients to the personal care and OTC topical
markets. As a technologically driven provider of high performance,
proprietary oleosome-based ingredients, Botaneco is committed to
developing groundbreaking ingredients that offer multifunctional,
tangible and documented benefits to both formulators and consumers.
Botaneco's manufacturing facility is located in Calgary, Canada while
its sales and marketing and research and development laboratories are
in Bensalem PA. More information is available and can be accessed at
http://www.botaneco.ca.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology
company developing protein-based pharmaceuticals for metabolic and
cardiovascular diseases. The Company's lead pharmaceutical
candidates, produced in the plant host safflower, are recombinant
human insulin to serve the rapidly expanding global diabetes market
and Apo AI, a next generation cardiovascular drug. In addition to its
pharmaceutical products, SemBioSys is developing a series of
non-pharmaceutical products addressing human topical, nutritional
oils and animal health markets. More information is available and can
be accessed at http://www.sembiosys.com.

About Croda International Plc

Croda International is a UK-based manufacturer of speciality
ingredients derived mainly from naturally occurring and renewable raw
materials. The market-driven company is renowned for its scientific
and technological focus, supplying innovative and sustainable
ingredients to global consumer care and industrial specialities
markets. Its broad product range includes skin, hair and sun care
actives, proteins and derivatives, high purity lipid concentrates,
lanolins, and polymeric surfactants used in many personal care, home
care, health care and crop care applications. Globally Croda
International Plc had sales of pnds stlg 886.1m (USD1.76b) in 2007,
and recorded a pre-tax trading profit of pnds stlg 60.9m (USD121.2m)
for continuing operations. The group employs over 3700 people
worldwide, with an extensive sales and distribution network covering
more than 60 countries. http://www.croda.com

This press release contains certain forward-looking statements,
including, without limitation, statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and other similar expressions which
constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. Forward-looking statements
reflect the Company's current expectation and assumptions, and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including,
but not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new
product development, uncertainties related to the regulatory approval
process and other risks detailed from time-to-time in the Company's
ongoing filings with the Canadian securities regulatory authorities
which filings can be found at http://www.sedar.com. Given these risks
and uncertainties, readers are cautioned not to place undue reliance
on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking
statements either as a result of new information, future events or
otherwise, except as required by applicable Canadian securities laws.

Internet: http://www.botaneco.ca/

For further information: Business Contact, Andrew Baum, Botaneco,
Ph: +1-403-717-8767, Fax: +1-403-250-3886, Email: bauma@sembiosys.com

ots Originaltext: SemBioSys, Genetics Inc
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Business Contact, Andrew Baum, Botaneco, Ph:
+1-403-717-8767, Fax: +1-403-250-3886, Email: bauma@sembiosys.com